| ²é¿´: 136 | »Ø¸´: 0 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
Ñî¹ýÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)
|
[½»Á÷]
Science Direct ¸ß¼¶¼¼ÇÉ
|
||
|
1 ΪʲôҪע²á ×¢²áºó¾Í¿ÉÒÔÏíÊÜһЩ·þÎñ,±ÈÈçmy ÌáÐÑ)µÄ¹¦ÄÜ,¿ÉÒÔ´¢´æ¼ìË÷²ßÂÔ,µ±ÓÐеķûºÏÄãÒªÇóµÄÎÄÏ׳öÏÖÒÔºó,¿ÉÒÔͨ¹ýµç×ÓÓʼþÌáÐÑÄã. ÔÚ±ÈÈç¼ìË÷ÀúÊ·,Ò²ÐèҪע²áºó²ÅÏíÓÐ,Äã¿ÉÒԲ鿴¼ìË÷ÀúÊ·,²¢ÇÒ¿ÉÒÔ½«ÒѾÓеļìË÷´ÊÓò¼¶ûËã·ûÁ¬ÆðÀ´¼ìË÷. 2 sd µÄÏÞÖÆ×Ö¶Î Journal-Name,title,authors,references,abstracts,keywords,text,full-text ¸ñʽ:authors(benabid) ,keywords(epilepsy) Èç¹û²»ÏÞÖÆµÄ»°£¬ËùÊäÈëµÄ´Ê¿ÉÒÔλÓÚ×÷Õߣ¬±êÌ⣬ÎÄÕª£¬²Î¿¼ÎÄÏ×£¬ÕýÎÄÖУ® 3 sdµÄ LexisNexisÂß¼Ëã·û 1)¾¡Á¿Ê¹ÓÃ×îÌùÇеĴÊ,Ò²Òª¿¼ÂÇͬÒå´Ê,½üÒå´Ê,Ëõд´ÊµÈ Èç:kidney disease OR renal failure,mri OR magnetic resonance imaging. 2)×÷Õß¼ìË÷ÐÕÒ»¶¨Òª¸ø³öÈ«³Æ,ÍÆ¼öauthors (ÐÕ W/3 ij×Öĸ£© ¡¡È磺authors(benabid w/3 a)Æä½á¹û°üÀ¨Benabid A L,A L Benabid, Benabid A, ÆäÖеÄw ±íʾÔÚbenabid ºÍa Ö®¼ä¿ÉÒÔÓУ³¸öwords, 3)½Ø´Ê·ûºÅ£¡£¬¿ÉÒԽضà¸ö´Ê£¬Ê¹Ó㪽ص¥¸ö´Ê ¡¡Èçcit!½«»áÕÒµ½city,cities,city's 4)stop wordsÓöµ½ÏÂÁдÊʱϵͳ²»»á¼ìË÷£¬¹Ú´Ê£¨a,an ,the ),´ú´Ê£¨i,you ,heµÈ£©£¬Ïµ¶¯´Ê£¨is ,be,are),Á¬´Ê£¨if ,then ,becauseµÈ) ¡¡Èçkeywords(profit and loss),ϵͳ½«¼ìË÷´Ê×éprofit loss 5)ÆäËûÓï·¨£º ¡¡NOT W/n,³öÏָôʣ¬µ«ÊDz»ÔÚn¸ö´ÊÒÔÄÚ ¡¡PRE/nn£¬¸Ã´ÊλÓÚλÓÚǰn¸ö´ÊÒÔÄÚ ¡¡W/SEG£¬Á½´ÊλÓÚÏàͬµÄÏÞÖÆÐÔ×Ö¶ÎÄÚ £¶£©¸÷¸öÓï·¨µÄÓÐÏÞÔËËã˳Ðò,ʹÓÃÀ¨ºÅ¿ÉÒԸıä˳Ðò OR W/nn PRE/nn NOT W/nn W/SEG NOT W/SEG AND AND NOT ÀýÈ磺pain W/15 morphine AND ganglia OR tumor OR¡¡lesion W/5 malignant ¼ìË÷µÄ˳Ðò£º£±£©º¬ÓÐganglia £¬lesion ,tumorµÈ´Ê £²£©Óëlesion ÔÚ£µ¸÷´ÊÒÔÄڵĴÊmaligant £³£©pain ¼°ÓëmorphineÔÚ£±£µ¸ö´ÊÒÔÄÚ £·£©ÆäËû£ºÏ£À°×Öĸ£¬Êý×Ö£¬ÆäËûÓïÖÖÎÄ×Öת³ÉÓ¢ÎÄ£¬Á¬´Ê·ûºÅÈ¡Ïû£¬ ÈçK£¨kappa),2(two),F¨¹rst(Furst),high-risk(high risk) |
» ²ÂÄãϲ»¶
312Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
ÍøÂç¿Õ¼ä°²È«0839Õе÷¼Á
ÒѾÓÐ4È˻ظ´
329Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
¡¾2026¿¼Ñе÷¼Á¡¿ÖÆÒ©¹¤³Ì 284·Ö ÇóÏà¹Ø×¨Òµµ÷¼ÁÃû¶î
ÒѾÓÐ8È˻ظ´
085602 289·ÖÇóµ÷¼Á
ÒѾÓÐ7È˻ظ´
²ÄÁÏѧ˶333Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
¸÷λÀÏʦÄúºÃ£º±¾È˳õÊÔ372·Ö
ÒѾÓÐ6È˻ظ´
334·Ö Ò»Ö¾Ô¸ÎäÀí-080500 ²ÄÁÏÇóµ÷¼Á
ÒѾÓÐ3È˻ظ´
0854µç×ÓÐÅÏ¢Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
347Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´














»Ø¸´´ËÂ¥